In a recent development, vaccine maker Moderna has announced positive late-stage trial results for its Covid-flu combination vaccine, known as mRNA-1083. The Chief Medical Affairs Officer, Francesca Ceddia, described the outcome of the trial as “breakthrough results,” highlighting an improved immune response in trial participants who received mRNA-1083 compared to those who received standalone flu and Covid vaccines currently available.
Moderna’s Phase 3 trial, a randomized, observer-blind, active control study, involved around 4,000 adults in two different age groups. The study demonstrated a statistically significant higher immune response against three strains of the flu and Covid-19 with the experimental combination vaccine compared to co-administered shots.
Other companies have also been testing combined Covid-flu vaccines, but Moderna is the first to announce positive late-stage trial results. The company plans to present data from the trial at an upcoming medical conference and submit it for publication. Moderna aims to have the combined vaccine approved for fall 2025.
Public health leaders have emphasized the need for more ways to protect against both viruses, as millions of people get sick with the flu and Covid each year. A combined shot could significantly benefit public health and help boost vaccine uptake, especially as vaccine hesitancy and fatigue increase post-pandemic. Sue Peschin, president and CEO of the Alliance for Aging Research, expressed support for the combined vaccine and urged regulatory approval if deemed safe and effective.
While only about 25% of the eligible population has received the latest Covid-19 vaccine, nearly half of adults received the flu shot last season, according to CDC data. Combining vaccines could be a potential solution to increase vaccination rates and protect the community.
